|
1
|
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
|
Cancer Res
|
2006
|
4.43
|
|
2
|
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
|
Clin Cancer Res
|
2002
|
3.14
|
|
3
|
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.
|
Nat Biotechnol
|
2006
|
2.66
|
|
4
|
Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids.
|
PLoS One
|
2007
|
2.28
|
|
5
|
A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.
|
Cancer Res
|
2004
|
2.00
|
|
6
|
Antibodies from phage antibody libraries.
|
J Immunol Methods
|
2004
|
1.75
|
|
7
|
Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.
|
Vaccine
|
2002
|
1.69
|
|
8
|
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.
|
Cancer Res
|
2011
|
1.62
|
|
9
|
Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.
|
J Infect Dis
|
2002
|
1.61
|
|
10
|
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4.
|
J Mol Biol
|
2006
|
1.59
|
|
11
|
Development of ligand-targeted liposomes for cancer therapy.
|
Expert Opin Ther Targets
|
2004
|
1.48
|
|
12
|
Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.
|
J Mol Biol
|
2007
|
1.48
|
|
13
|
Antibody protection against botulinum neurotoxin intoxication in mice.
|
Infect Immun
|
2009
|
1.43
|
|
14
|
Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.
|
Cancer Res
|
2005
|
1.38
|
|
15
|
Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.
|
PLoS One
|
2009
|
1.35
|
|
16
|
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
|
Cancer Res
|
2003
|
1.33
|
|
17
|
Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
|
J Immunol
|
2007
|
1.32
|
|
18
|
Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?
|
Methods Mol Biol
|
2009
|
1.32
|
|
19
|
Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS.
|
PLoS One
|
2010
|
1.28
|
|
20
|
Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.
|
Clin Cancer Res
|
2006
|
1.26
|
|
21
|
Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β.
|
J Clin Invest
|
2011
|
1.25
|
|
22
|
Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells.
|
Cancer Res
|
2004
|
1.25
|
|
23
|
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.
|
Mol Cancer Ther
|
2007
|
1.22
|
|
24
|
Phage versus phagemid libraries for generation of human monoclonal antibodies.
|
J Mol Biol
|
2002
|
1.18
|
|
25
|
Affinity thresholds for membrane fusion triggering by viral glycoproteins.
|
J Virol
|
2007
|
1.11
|
|
26
|
A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region.
|
J Mol Biol
|
2010
|
1.10
|
|
27
|
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
|
Biochim Biophys Acta
|
2002
|
1.08
|
|
28
|
The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies.
|
J Mol Biol
|
2002
|
1.08
|
|
29
|
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.
|
Mol Immunol
|
2007
|
1.07
|
|
30
|
Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis.
|
Biotechnol Prog
|
2005
|
1.06
|
|
31
|
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
|
Cancer Biother Radiopharm
|
2005
|
1.06
|
|
32
|
An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.
|
Eur J Nucl Med Mol Imaging
|
2010
|
1.05
|
|
33
|
Towards proteome-wide production of monoclonal antibody by phage display.
|
J Mol Biol
|
2002
|
1.05
|
|
34
|
Using phage display to select antibodies recognizing post-translational modifications independently of sequence context.
|
Mol Cell Proteomics
|
2006
|
1.00
|
|
35
|
Yeast mating for combinatorial Fab library generation and surface display.
|
FEBS Lett
|
2004
|
0.99
|
|
36
|
Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.
|
J Mol Med (Berl)
|
2007
|
0.99
|
|
37
|
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.
|
Clin Cancer Res
|
2008
|
0.99
|
|
38
|
Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification.
|
Biotechnol Prog
|
2005
|
0.98
|
|
39
|
Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy.
|
J Biol Chem
|
2007
|
0.98
|
|
40
|
Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.
|
J Immunother
|
2007
|
0.96
|
|
41
|
Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.
|
Cancer Chemother Pharmacol
|
2009
|
0.95
|
|
42
|
A novel assay for monitoring internalization of nanocarrier coupled antibodies.
|
BMC Immunol
|
2006
|
0.95
|
|
43
|
Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies.
|
J Immunol Methods
|
2004
|
0.94
|
|
44
|
Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
|
Cancer Res
|
2009
|
0.93
|
|
45
|
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
|
Mol Cancer Ther
|
2012
|
0.92
|
|
46
|
Tumor detection by imaging proteolytic activity.
|
Cancer Res
|
2010
|
0.92
|
|
47
|
Development of a highly stable and targetable nanoliposomal formulation of topotecan.
|
J Control Release
|
2009
|
0.92
|
|
48
|
Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.
|
J Mol Med (Berl)
|
2009
|
0.92
|
|
49
|
Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines.
|
Clin Cancer Res
|
2008
|
0.90
|
|
50
|
An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.
|
Mol Imaging Biol
|
2012
|
0.90
|
|
51
|
Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens.
|
J Mol Biol
|
2010
|
0.89
|
|
52
|
Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
|
Mol Cancer Ther
|
2011
|
0.89
|
|
53
|
Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies.
|
Anal Chim Acta
|
2006
|
0.88
|
|
54
|
Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.
|
J Biol Chem
|
2011
|
0.88
|
|
55
|
N-Terminal labeling of filamentous phage to create cancer marker imaging agents.
|
ACS Nano
|
2012
|
0.88
|
|
56
|
Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies.
|
Biosens Bioelectron
|
2009
|
0.87
|
|
57
|
A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test.
|
Anal Biochem
|
2012
|
0.87
|
|
58
|
Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E.
|
Biochem J
|
2013
|
0.86
|
|
59
|
Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies.
|
BMC Biochem
|
2011
|
0.85
|
|
60
|
Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.
|
Clin Cancer Res
|
2010
|
0.84
|
|
61
|
Renewable surface fluorescence sandwich immunoassay biosensor for rapid sensitive botulinum toxin detection in an automated fluidic format.
|
Analyst
|
2009
|
0.84
|
|
62
|
Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas.
|
Cancer Res
|
2010
|
0.83
|
|
63
|
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies.
|
Eur J Immunol
|
2002
|
0.82
|
|
64
|
Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays.
|
Anal Biochem
|
2012
|
0.82
|
|
65
|
Phage-display antibody detection of Chlamydia trachomatis-associated antigens.
|
Microbiology
|
2002
|
0.82
|
|
66
|
Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity.
|
Anal Chem
|
2009
|
0.81
|
|
67
|
RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin.
|
Talanta
|
2013
|
0.80
|
|
68
|
Development and Implementation of Checklists for Routine Anesthesia Care: A Proposal for Improving Patient Safety.
|
Anesth Analg
|
2015
|
0.79
|
|
69
|
Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes.
|
Biotechnol Bioeng
|
2011
|
0.79
|
|
70
|
Building and characterizing antibody-targeted lipidic nanotherapeutics.
|
Methods Enzymol
|
2012
|
0.79
|
|
71
|
Development of human single-chain antibodies against SARS-associated coronavirus.
|
Intervirology
|
2008
|
0.79
|
|
72
|
Identification of target and function specific antibodies for effective drug delivery.
|
Methods Mol Biol
|
2009
|
0.79
|
|
73
|
Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins.
|
Analyst
|
2014
|
0.78
|
|
74
|
Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism.
|
J Med Microbiol
|
2013
|
0.78
|
|
75
|
Identifying blood-brain-barrier selective single-chain antibody fragments.
|
Biotechnol J
|
2014
|
0.77
|
|
76
|
Selection and characterization of cell binding and internalizing phage antibodies.
|
Arch Biochem Biophys
|
2012
|
0.77
|
|
77
|
Discovery of internalizing antibodies to tumor antigens from phage libraries.
|
Methods Enzymol
|
2012
|
0.77
|
|
78
|
TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS.
|
Am J Transl Res
|
2010
|
0.76
|
|
79
|
Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor.
|
Sarcoma
|
2012
|
0.76
|
|
80
|
Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron.
|
J Immunol Methods
|
2004
|
0.75
|
|
81
|
Predicting antigenic peptides suitable for the selection of phage antibodies.
|
Hum Antibodies
|
2003
|
0.75
|